Drug intelligence / Profile preview

NW Roselle

Development stage: Unknown
Lead developer: Natural Wellness
Modality: Small Molecules
Administration: Oral

Overview

NW Roselle is a standardized herbal medicinal product developed by Natural Wellness Egypt for the treatment of Grade 1 essential hypertension. It consists of a combination of extracts from Hibiscus sabdariffa (roselle) calyxes and Olea europaea (olive) leaves. The therapeutic effect is primarily attributed to the inhibition of angiotensin-converting enzyme (ACE) by constituents of the olive leaf extract, complemented by the antihypertensive properties of roselle. Clinical evaluation in Phase II and Phase III trials has shown the product to have comparable efficacy and safety to the standard ACE inhibitor captopril.

Brand names: NW Roselle
Other names: Hibiscus sabdariffa + Olea europaea extract

Targets

ACE (Angiotensin Converting Enzyme)

Beyond the preview

Go deeper on NW Roselle.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NW Roselle.

Explore the full profile